Tech Company Financing Transactions
Amicus Therapeutics Funding Round
Amicus Therapeutics closed a $25 million funding round on 12/31/2013. Investors included MidCap Financial, Oxford Finance and Silicon Valley Bank.
Transaction Overview
Company Name
Announced On
12/31/2013
Transaction Type
Debt
Amount
$25,000,000
Round
Undisclosed
Proceeds Purpose
Proceeds from the transactions will be used to advance the development of the company's next-generation therapies for Fabry, Pompe and other lysosomal storage diseases (LSDs) utilizing its proprietary chaperone-advanced replacement therapy (CHART) platform technology. The company projects that the current cash position, including the proceeds from the private placement and debt financings, are sufficient to fund operations into the second half of 2015.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Cedar Brook Dr.
Cranbury, NJ 08512
USA
Cranbury, NJ 08512
USA
Phone
Website
Email Address
Overview
Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases. The Company has a robust development pipeline of treatments for a range of human genetic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Crowley
Chief Medical Officer
Jay Barth
Chief Operating Officer
Bradley Campbell
Chief Scientific Officer
Hung Do
Vice President
Jeffrey Castelli
VP - Finance
Daphne Quimi
Browse more venture capital transactions:
Prev: 12/31/2013: Conventus Orthopaedics venture capital transaction
Next: 12/31/2013: Pulse8 venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs